Elevated circulating levels of inflammatory biomarkers (e.g., interleukin-1β (IL-1β), interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α)) caused by aberrant immune activation is closely involved in stroke occurrence [7], while some medications with well-documented anti-inflammatory capacities—such as statins and canakinumab (also known as a humanized monoclonal antibody against IL-1β)—have been proven to lower the risk of stroke [8, 9], reflecting that chronic low-grade inflammatory status is a key event predisposing to stroke. This evidence concerns the gene IL6 and Stroke.